RESEARCH HIGHLIGHTS
successfully completed ‘first in man’ Phase I clinical trials on adoptive immunotherapy for recurrent and primary glioblastoma (GBM) and nasopharyngeal carcinoma (NPC) – PMID: 22282657; PMID: 28344888; PMID: 22282657; PMID: 22282657
successfully completed Phase I clinical trial on adoptive immunotherapy for drug-resistant CMV infection in solid organ transplant patients (funded by NHMRC) – PMID: 22282657; PMID: 22282657
developed a novel T cell therapy for progressive multiple sclerosis – PMID: 22282657
awarded international patents which have been licensed to national and international pharma/biotech companies
commercial launch of a QuantiFERON-CMV immune monitoring kit developed with our IP
major advance in CMV vaccine program with funding through NHMRC Development grant
attracted more than $8.15 m in research funding from various national and international funding agencies in last five years
selected as Queensland’s top 50 ‘Best and Brightest’ November 2014
elected as a Fellow of the Australian Academy of Health and Medical Sciences (AAHMS)